These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2137668)

  • 1. Differential hemodynamic effects of oral enoximone in severe congestive heart failure.
    Murali S; Uretsky BF; Betschart AR; Tokarczyk TR; Kolesar JA; Reddy PS
    Am J Cardiol; 1990 Feb; 65(7):515-9. PubMed ID: 2137668
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of low dose enoximone for chronic congestive heart failure.
    Jessup M; Ulrich S; Samaha J; Helfer D
    Am J Cardiol; 1987 Aug; 60(5):80C-84C. PubMed ID: 2956875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure.
    Leier CV; Meiler SE; Matthews S; Unverferth DV
    Am J Cardiol; 1987 Aug; 60(5):27C-30C. PubMed ID: 2956864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation.
    Khalife K; Zannad F; Brunotte F; Belhadj K; Juilliere Y; Iannascoli F; Gilgenkrantz JM
    Am J Cardiol; 1987 Aug; 60(5):75C-79C. PubMed ID: 2956874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study.
    Gilbert EM; Bristow MR; Mason JW
    Am J Cardiol; 1987 Aug; 60(5):57C-62C. PubMed ID: 2956870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
    Tommaso CL
    Am J Med; 1986 Feb; 80(2B):36-9. PubMed ID: 3004210
    [No Abstract]   [Full Text] [Related]  

  • 7. A dose-response study of intravenous enoximone in congestive heart failure.
    Erbel R; Meyer J; Diefenbach C; Delorme G; Bourdarias JP; Vernant P; Lellouche D; Mattioli G; Barbieri A; Installe E
    Am J Cardiol; 1987 Aug; 60(5):31C-36C. PubMed ID: 2956865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure.
    Zipperle G; Butzer F; Dieterich HA; Heinrich F
    Am J Cardiol; 1987 Aug; 60(5):72C-74C. PubMed ID: 2956873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.
    Kereiakes D; Chatterjee K; Parmley WW; Atherton B; Curran D; Kereiakes A; Spangenberg R
    J Am Coll Cardiol; 1984 Nov; 4(5):884-9. PubMed ID: 6238076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic effects of enoximone in patients with congestive heart failure.
    Hohnloser SH; Zehender M; Geibel A; Meinertz T; Just H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S29-32. PubMed ID: 2480482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of chronic cardiac insufficiency with intravenous bolus enoximone. Study of a pharmacokinetic-hemodynamic relation].
    Gibelin P; Garraffo R; Sbirrazzuoli V; Lapalus P; Morand P
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():75-81. PubMed ID: 2147839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure.
    Uretsky BF; Generalovich T; Verbalis JG; Valdes AM; Reddy PS
    Am J Cardiol; 1986 Jul; 58(1):110-6. PubMed ID: 2942027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enoximone].
    Ventura G
    Medicina (Firenze); 1990; 10(2):191-3. PubMed ID: 2148796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous use of enoximone.
    Crawford MH
    Am J Cardiol; 1987 Aug; 60(5):42C-45C. PubMed ID: 2956867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF; Valdes AM; Reddy PS
    Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].
    Saborowski F; Peters P; Schneider M
    Z Kardiol; 1991; 80 Suppl 4():63-7. PubMed ID: 1833900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of hemodynamic effects of one-month oral captopril and enoximone treatment for severe congestive heart failure.
    Scriven AJ; Lipkin DP; Anand IS; Sutton GC; Poole-Wilson PA
    Am J Cardiol; 1987 Aug; 60(5):68C-71C. PubMed ID: 2956872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oral enoximone therapy in chronic cardiac failure.
    Maskin CS; Weber KT; Janicki JS
    Am J Cardiol; 1987 Aug; 60(5):63C-67C. PubMed ID: 2956871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoximone.
    Lancet; 1988 May; 1(8594):1085-6. PubMed ID: 2896916
    [No Abstract]   [Full Text] [Related]  

  • 20. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.